Cyclerion Therapeutics, Inc.
CYCN
$3.13
-$0.05-1.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.70% | 1,371.65% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.70% | 1,371.65% | -- | -- | -- |
| Cost of Revenue | 235.31% | 818.52% | -58.59% | -64.68% | -78.25% |
| Gross Profit | -34.95% | 1,585.00% | 451.72% | 329.10% | 230.34% |
| SG&A Expenses | 13.96% | -1.20% | -18.04% | -26.83% | -35.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.21% | 6.03% | -21.03% | -30.55% | -41.65% |
| Operating Income | -37.07% | 38.68% | 49.99% | 56.60% | 62.39% |
| Income Before Tax | -15.41% | 58.36% | 81.41% | 73.11% | 75.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.41% | 58.36% | 81.41% | 73.11% | 75.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.41% | 58.36% | -164.69% | -2,075.84% | 41.92% |
| EBIT | -37.07% | 38.68% | 49.99% | 56.60% | 62.39% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 3.75% | 64.23% | -158.35% | -3,393.99% | 53.17% |
| Normalized Basic EPS | -31.31% | 44.02% | 59.68% | 63.27% | 69.54% |
| EPS Diluted | 3.75% | 64.24% | -158.38% | -3,322.06% | 53.18% |
| Normalized Diluted EPS | -31.31% | 44.02% | 59.68% | 63.27% | 69.54% |
| Average Basic Shares Outstanding | 25.72% | 14.11% | 8.10% | 4.84% | 7.74% |
| Average Diluted Shares Outstanding | 25.72% | 14.11% | 8.10% | 4.84% | 7.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |